LETTER TO THE EDITOR
Main Article Content
Keywords
Public reimbursement, off lable, prescription drugs
Abstract
Author's response to comments from Dr Lexchin's Letter to the Editor regarding our article.
References
1. Rawson NSB, Chhabra A. Public reimbursement of prescription drugs used for off-label indications in Ontario. J Popul Ther Clin Pharmacol 2018;25:e23-30.
2. Canadian Agency for Drugs and Technologies in Health. Anti-vascular endothelial growth factor (VEGF) drugs for the treatment of retinal conditions: recommendations report (May 2016). https://www.cadth.ca/sites/default/files/pdf/TR0009_Anti-VEGFs_Recs_Report.pdf (accessed on: November 20, 2018).
3. Lexchin J. Editorial. J Popul Ther Clin Pharmacol 2018;25:e31-2.
4. Avastin Product Monograph (June 6, 2018). http://www.rochecanada.com/content/dam/roche_canada/en_CA/documents/Research/ClinicalTrialsForms/Products/ConsumerInformation/MonographsandPublicAdvisories/Avastin/Avastin_PM_E.pdf (accessed on: November 20, 2018).
5. Rawson NSB, Adams J. Do reimbursement recommendation processes used by government drug plans in Canada adhere to good governance principles? Clinicoecon Outcomes Res 2017;9:721–30.
2. Canadian Agency for Drugs and Technologies in Health. Anti-vascular endothelial growth factor (VEGF) drugs for the treatment of retinal conditions: recommendations report (May 2016). https://www.cadth.ca/sites/default/files/pdf/TR0009_Anti-VEGFs_Recs_Report.pdf (accessed on: November 20, 2018).
3. Lexchin J. Editorial. J Popul Ther Clin Pharmacol 2018;25:e31-2.
4. Avastin Product Monograph (June 6, 2018). http://www.rochecanada.com/content/dam/roche_canada/en_CA/documents/Research/ClinicalTrialsForms/Products/ConsumerInformation/MonographsandPublicAdvisories/Avastin/Avastin_PM_E.pdf (accessed on: November 20, 2018).
5. Rawson NSB, Adams J. Do reimbursement recommendation processes used by government drug plans in Canada adhere to good governance principles? Clinicoecon Outcomes Res 2017;9:721–30.
Article Sidebar
Published
Jan 22, 2019
Article Details
How to Cite
Rawson, N. S. (2019). LETTER TO THE EDITOR. Journal of Population Therapeutics and Clinical Pharmacology, 26(1), e20-e21. https://doi.org/10.22374/1710-6222.26.1.2
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
Rawson, N. S. (2019). LETTER TO THE EDITOR. Journal of Population Therapeutics and Clinical Pharmacology, 26(1), e20-e21. https://doi.org/10.22374/1710-6222.26.1.2